Status and phase
Conditions
Treatments
About
The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 5 patient groups, including a placebo group
Loading...
Central trial contact
Hongzhou Yang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal